India's Dr. Reddy's Laboratories announced it has entered into a licensing agreement with Japan's Eisai for exclusive worldwide development and commercialization rights (excluding Japan and Asia) for Eisai’s investigational anticancer agent, E7777.
Eisai will be responsible for the development and marketing of E7777 in Japan and Asia, while Dr. Reddy’s holds the option for rights to develop and market the agent in India, U.S., Russia and Venezuela.
Financials of the deal were not disclosed, but Eisai will receive milestone payments in line with obtaining marketing approval and the achievement of agreed upon sales targets.
According to Eisai, a phase 2 clinical study of E7777 in patients with cutaneous T-cell lymphoma or peripheral T-cell lymphoma is currently underway in Japan. Preparations are simultaneously in progress for a phase 3 clinical study in patients with cutaneous T-cell lymphoma in the U.S.
Read the Street Insider coverage